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Mutations in ZBTB24 Are Associated
with Immunodeficiency, Centromeric Instability,
and Facial Anomalies Syndrome Type 2
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Autosomal-recessive immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome is mainly characterized by recur-
rent, often fatal, respiratory and gastrointestinal infections. About 50% of patients carry mutations in the DNA methyltransferase 3B
gene (DNMT3B) (ICF1). The remaining patients carry unknown genetic defects (ICF2) but share with ICF1 patients the same immuno-
logical and epigenetic features, including hypomethylation of juxtacentromeric repeat sequences. We performed homozygosity
mapping in five unrelated ICF2 patients with consanguineous parents and then performed whole-exome sequencing in one of these
patients and Sanger sequencing in all to identify mutations in the zinc-finger- and BTB (bric-a-bric, tramtrack, broad complex)-
domain-containing 24 (ZBTB24) gene in four consanguineously descended ICF2 patients. Additionally, we found ZBTB24 mutations
in an affected sibling pair and in one patient for whom it was not known whether his parents were consanguineous. ZBTB24 belongs
to a large family of transcriptional repressors that include members, such as BCL6 and PATZ1, with prominent regulatory roles in
hematopoietic development andmalignancy. These data thus indicate that ZBTB24 is involved in DNAmethylation of juxtacentromeric
DNA and in B cell development and/or B and T cell interactions. Because ZBTB24 is a putative DNA-binding protein highly expressed in
the lymphoid lineage, we predict that by studying the molecular function of ZBTB24, we will improve our understanding of the molec-
ular pathophysiology of ICF syndrome and of lymphocyte biology in general.Patientswithautosomal-recessive immunodeficiency, centro-
meric instability, and facial anomalies (ICF [MIM 242860])
syndrome suffer from recurrent and often fatal respiratory
and gastrointestinal infections because of hypogammaglobu-
linemia, even in the presence of normal B cell counts. ICF
syndrome also presents with facial anomalies, most notably
a broad and flat nasal bridge, hypertelorism, and epicanthal
folds. The molecular hallmark of this condition is the
presence of chromosomal abnormalities in phytohemagglu-
tinin (PHA)-stimulated peripheral blood lymphocytes (PBLs)
of patients. These abnormalities are not restricted to hema-
topoietic cell lineages and include the formation of radial
chromosomes involving the juxtacentromeric heterochro-
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DNA methyltransferase 3B gene (DNMT3B [MIM 602900)]
at chromosomal locus 20q11.2 (these cases are said to have
ICF1).3,4 DNMT3B is one of the three main mammalian
DNA methyltransferases that play an important but not
exclusive role in de novo DNA methylation.5 In ICF1
patients, the enzymatic activity of DNMT3B is strongly,
but not completely, reduced,6 and as a consequence,
specific genomic regions of ICF patients show significant
loss of DNA methylation. This hypomethylation is most
strongly observed in satellite 2 (Sat2) repeats on the long
arm of chromosomes 1 and 16, satellite 3 (Sat3) repeats
on the long arm of chromosome 9, and in the nonsatellite
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Figure 1. Genetics and Epigenetics of ICF2 Patients
(A) Pedigrees of 11 ICF2 families studied. The parents of P1, P2, P3, and P4 were first-degree relatives. The great-grandmothers of patient
P5 were sisters. The history of consanguinity for P10 was unknown before this study. However, our SNP array data show large regions of
homozygosity, suggesting that the parents of P10 are related (data not shown).
(B) a-satellite hypomethylation in ICF2 patients. Southern-blot analysis of the a-satellite repeat on chromosome 9 in a control
individual, an ICF1 patient with a DNMT3Bmutation, two ICF2 patients (P1 and P5) with a mutation in ZBTB24, and one ICF2 patient
(P4) in whomnomutations inDNMT3B or ZBTB24were identified and inwhom theDNMT3B and ZBTB24 loci were excluded by homo-
zygosity mapping. DNA samples (2 mg) were digested overnight with the restriction enzymeHhaI, separated by linear gel electrophoresis
on a 0.8% agarose gel. Subsequently, Southern blotting of the DNA and hybridization of the resultingmembranewith a probe targeted to
the a-satellite repeat on chromosome 9 were performed.48the subtelomeres of the long arms of chromosomes 4 and
10.7,8
In the remainder of ICF patients, noDNMT3Bmutations
can be found (these cases are said to have ICF2).9 These
patients are clinically identical to ICF1 patients,2 but
they have additional DNA hypomethylation of a-satellite
repeats.10 In two ICF2 patients, the DNMT3B locus was
excluded by haplotype analysis,9 and the most common
splice variant of DNMT3B mRNA was detected in several
ICF2 patients.10 Furthermore, in one ICF2 patient no
mutations were identified in two putative DNMT3B pro-
moter regions,11 and no evidence for changes in DNMT3B
splicing was obtained in another ICF2 patient.12 We there-
fore hypothesized that the ICF syndrome is genetically
heterogeneous.
For our studies genomic DNAwas available from 11 ICF2
patients (Figure 1A and Table 1).
All studies were carried out with informed consent of the
probands or their legal guardians and were approved by
the institutional ethic review board of the Radboud
University Nijmegen Medical Centre. P1 (II.1 in family
P1 in Figure 1A) is a consanguineously descended Turkish
male patient with agammaglobulinemia, facial anomalies,
motor development delay, and mental retardation. We
found no DNMT3B mutation, but we did observe a-satel-
lite hypomethylation indicative of ICF2 (Figure 1B).10 P2
(II.1 in family P2 in Figure 1A) was a consanguineously de-
scended Scottish female patient who presented with agam-
maglobulinemia, facial anomalies, motor development
delay, and mental retardation and who was previously
included in the homozygosity mapping study aimed at
identifying the gene in which variation is associated withThe AmeICF1.13 However, she did not show autozygosity for the
DNMT3B locus, and no DNMT3B mutation was identi-
fied.14 P3 (II.1 in family P3 in Figure 1A) was a consanguin-
eously descended Dutch female patient of Turkish descent.
This patient was also part of the patient cohort used for
identification of the gene in which variation is associated
with ICF1, and she did not show autozygosity for the
DNMT3B locus either.14 In addition, no DNMT3B muta-
tion was identified.9 She presented with agammaglobulin-
emia, facial anomalies, motor development delay, and
mental retardation.14 Because of limitedmaterial, we could
not perform a-satellite DNA methylation analysis in
patients P2 and P3. P4 (II.2 in family P4 in Figure 1A) is
a consanguineously descended Turkish male patient with
agammaglobulinemia, facial anomalies, and mental retar-
dation. We observed a-satellite DNA hypomethylation in
this patient (Figure 1B); we could not detect a mutation
in DNMT3B. P5 (II.1 in family P5 in Figure 1A) is a consan-
guineously descended Belgian male patient of Turkish
descent who presented with agammaglobulinemia, facial
anomalies, and mental retardation. We did not identify
a DNMT3B mutation, but we did observe a-satellite hypo-
methylation (Figure 1B). P6 (II.1 in family P6/P7 in
Figure 1A) and P7 (II.2 in family P6/P7 in Figure 1A) were
a German brother and sister with no known history of
consanguinity. Both presented with facial anomalies,
mental retardation, and agammaglobulinemia or hypo-
gammaglobulinemia. In addition, P7 presented with
a motor development delay. No DNMT3B mutation was
observed in either patient, but both patients showed
a-satellite hypomethylation.15 P8 (II.1 in family P8/P9 in
Figure 1A) and P9 (II.2 in family P8/P9 in Figure 1A) arerican Journal of Human Genetics 88, 796–804, June 10, 2011 797
Table 1. Clinical and Genetic Data of ICF2 Patients
Case, Gender Clinical Phenotype Status Origin ZBTB24 Mutation
Number in
Hagleitner et al.2
P1, male agammaglobulinemia, facial
anomalies, motor development
delay, mental retardation
4 years old Turkish p.Asn306IlefsX4 (c.917delA) –
P2, female agammaglobulinemia, facial
anomalies, motor development
delay, mental retardation
died at age 13 Scottish p.Ser16X (c.47C>G) 11
P3, female agammaglobulinemia, facial
anomalies, motor development
delay, mental retardation
died at age 11 Turkish p.Arg320X (c.958C>T) 17
P4, male agammaglobulinemia, facial
anomalies, mental retardation
6 years old Turkish No mutation identified –
P5, male agammaglobulinemia, facial
anomalies, mental retardation
13 years old Turkish p.Val168SerfsX28 (c.501dup) –
P6, male agammaglobulinemia, facial
anomalies, mental retardation
died at age 4 German p.Ser278X (c.833C>G) and
p.Cys408Gly (c.1222T>G)
37
P7, female hypogammaglobulinemia, facial
anomalies, motor development
delay, mental retardation
9 years old German p.Ser278X (c.833C>G) and
p.Cys408Gly (c.1222T>G)
38
P8, female agammaglobulinemia, facial
anomalies, normal intelligence
11 years old British No mutation identified 34
P9, male agammaglobulinemia, facial
anomalies, normal intelligence
4 years old British No mutation identified –
P10, male hypogammaglobulinemia, facial
anomalies, mental retardation
adult Italian p.Arg457X (c.1369C>T) 6
P11, female IgM deficiency, facial anomalies,
mental retardation
adult Italian No mutation identified 13a British sister and brother who have no history of consan-
guinity. Initially, both presented with agammaglobulin-
emia and facial anomalies. The agammaglobulinemia in
P8 and P9 was corrected by hematopoietic stem cell trans-
plantation.2,16 We did not find DNMT3B mutations, but
we observed a-satellite hypomethylation (data not
shown). P10 (II.1 in family P10 in Figure 1A) is an Italian
male patient who has no known history of consanguinity
and who presented with hypogammaglobulinemia, facial
anomalies, and mental retardation.17 We did not detect
aDNMT3Bmutation. Finally, P11 (II.1 in family P11 in Fig-
ure 1A) is an Italian female patient with a IgM deficiency,
facial anomalies, mental retardation, and no known
history of consanguinity.18,19 No mutation was found in
DNMT3B. Because of scarcity of material, no a-satellite
DNA methylation analysis was performed in P10 and P11.
To identify genes in which variation is associated with
ICF, we performed homozygosity mapping20 in the five
unrelated ICF2 patients born to consanguineous parents
(P1–P5). We used the Sentrix HumanHap-300 Genotyping
BeadChips containing 317,503 loci of HapMap I and II
TagSNP (Illumina). Seven hundred and fifty nanograms
of DNAwas processed with the Infinium IIWhole-Genome
Genotyping Assay (Illumina). In short, DNAwas amplified,
fragmented, precipitated with ethanol, and resuspended.
Next, the DNAwas applied to the BeadChip and incubated
overnight; enzymatic base extension, fluorescent staining798 The American Journal of Human Genetics 88, 796–804, June 10,of the beads, and detection of fluorescent intensities by
the BeadArray Reader (Illumina) followed. Finally, to detect
regions of homozygosity, we assessed B allele frequencies
for all SNPs by using BeadStudio version 3.2 (Illumina).
Large regions of homozygosity were identified in all
patients and confirmed that the patients were each of
consanguineous descent. However, no region of homozy-
gosity was shared by all patients, suggesting that ICF2 itself
is also heterogeneous.
Next, we performed exome sequencing21 to study all
exons in the genome of one consanguineously descended
ICF2 patient (P3).14 Five micrograms of DNA was frag-
mented to yield 200–300 bp fragments with the Bioruptor
(Diagenode). End repair of DNA fragments was subse-
quently carried out per the manufacturer’s instructions
(New England Biolabs). Next, paired-end adaptor oligonu-
cleotides (Illumina) were added to the ends of the DNA
fragments, and the resulting DNA-adaptor-ligated frag-
ments were hybridized for 72 hr against the Sequence
Capture Human Exome 2.1M Array (Roche NimbleGen);
washing of unbound fragments and elution of the
exome-enriched pool of DNA followed. The eluted DNA
fragments were amplified with adaptor-specific primers
(Illumina) and Phusion DNA polymerase (Finnzymes).
Finally, the exome-enriched DNA fragments were se-
quenced with the Genome Analyzer IIx system (Illumina).
We prepared paired-end flow cells on the supplied cluster2011
station according to the manufacturer’s instructions. The
resulting reads were aligned to the reference human
genome (hg 19, NCBI build 37) by Bowtie software,22
and sequence variants were identified with SAMtools
software.23 In a homozygous region that was shared
between four of the five patients of consanguineous
descent, we identified a homozygous sequence variant
(c.958C>T; NM_014797.2) in exon 3 of the zinc-finger-
and BTB (bric-a-bric, tramtrack, broad complex)-domain-
containing (ZBTB24) gene. This sequence variant creating
a premature stop codon at amino acid position 320
(p.Arg320X; NP_055612.2) was confirmed by PCR amplifi-
cation of exon 3 of ZBTB24 and subsequent Sanger
sequencing (Figure 2A).
Finally, we performed mutation analysis in all ZBTB24
coding exons by PCR amplification and Sanger sequencing
in the remaining four consanguineously descended ICF2
patients (P1, P2, P4, and P5) and in the six additional ICF2
patients for whom genomic DNA was available (P6–P11).
The primers used for the ZBTB24 mutation analysis are
shown in Table S1, available online. We identified homozy-
gous ZBTB24 sequence variants in three additional consan-
guineously descended patients (P1, P2, and P5) and in one
patient for whom consanguineous descent had not been
previously established (P10). An affected sibling pair of non-
consanguineous descent was compound heterozygote for
ZBTB24 mutations (P6 and P7). We did not find any
ZBTB24 sequence variants in an affected sibling pair (P8
and P9), one patient of nonconsanguineous descent (P11),
oroneconsanguineouslydescendedpatient (P4), confirming
additional genetic heterogeneity. P4 was also excluded for
theZBTB24 locus basedonourhomozygositymappingdata.
P1 is homozygous for a 1 bp deletion in exon 2
(c.917delA; NM_014797.2), resulting in a frameshift and
a premature stop codon three amino acids downstream
(p.Asn306IlefsX4; NP_055612.2). P2 carries a homozygous
nonsense mutation in exon 2 (c.47C>G; NM_014797.2),
resulting in a serine-to-stop conversion (p.Ser16X;
NP_055612.2). P5 is homozygous for a 1 bp duplication
in exon 2 (c.501dup; NM_014797.2), resulting in a frame-
shift and a premature stop codon 27 amino acids down-
stream (p.Val168SerfsX28; NP_055612.2). P10 carries a
homozygous nonsense mutation in exon 6 (c.1369C>T;
NM_014797.2), resulting in an arginine-to-stop conver-
sion (p.Arg457X; NP_055612.2). Finally, P6 and P7 carried
a serine-to-stop nonsense mutation in exon 2 (c.833C>G,
p.Ser278X; NM_014797.2 and NP_055612.2) and a
cysteine-to-glycine missense mutation in exon 5
(c.1222T>G, p.Cys408Gly; NM_014797.2 andNP_055612.2);
the latter mutation affects a conserved cysteine in one of
the eight C2H2 zinc fingers of the ZBTB24 protein. In
conclusion, all but one of the identified mutations created
premature stop codons in ZBTB24. This suggests that ICF2
is caused by loss-of-function mutations in ZBTB24. The
identified ZBTB24 mutations are summarized in Table 1;
Sanger sequencing results are shown in Figure 2A, and
the locations of the mutations in ZBTB24 are shown inThe AmeFigure 2B. Finally, in Table S2 the clinical and immunolog-
ical characteristics that the ICF2 patients with ZBTB24
mutations had at diagnosis are summarized and compared
with those that ICF1 patients with DNMT3B mutations
had at diagnosis, and no difference in phenotype between
ICF1 and ICF2 patients is revealed.
Using quantitative reverse transcriptase PCR (qRT-PCR),
we studied full-length ZBTB24 mRNA expression in
human primary cell cultures, tissues, and cell lines. In addi-
tion, we combined fluorescence-activated cell sorting
(FACS) analysis and qRT-PCR to study ZBTB24 mRNA
expression in subpopulations of normal human B cells,
CD4þ T cells, and natural killer (NK) cells more specifically.
We obtained human peripheral blood from two healthy
blood-bank donors after receiving informed consent.
Peripheral blood mononuclear cells (PBMCs) were isolated
by centrifugation over Ficoll-Hypaque density gradients.
CD19þ B cells were purified by positive selection with
the Dynabeads CD19 Pan B (Invitrogen) and then
detached by DETACHaBEAD CD19 (Invitrogen). Purified
B cells were then stained with a combination of
CD19percp-cy5.5 (SJ25C1), CD27phycoerythrin (L128),
IgMallophycocyanin (G20-127), and IgDfluorescein isothiocyanate
(IA6-2) antibodies. CD4þ T cells were purified by
positive selection with the Dynabeads FlowComp Human
CD4 T cell isolation kit (Invitrogen). Purified T cells
were then incubated with CD4pacific blue (RPA-T4),
CD45RAfluorescein isothiocyanate (L48), and CCR7alexa fluor 647
(3D12) antibodies. All antibodies were obtained from BD
Biosciences. The following cell fractions were sorted with
a FACS Aria cell sorter (Becton Dickinson) with greater
than 98% purity: total CD19þ, naive CD19þCD27-IgDþ,
unswitched memory CD19þCD27þIgDþIgMþ and
switched memory CD19þCD27þIgDIgM B cells, total
CD4þ, naive CD4þCD45RAþCCR7þ, and memory CD4þ
CD45RATcells. The analysis and sort gates were restricted
to the small lymphocyte gate as determined by their char-
acteristic forward and side-scatter properties. NK cells were
isolated with the MACS NK Cell Isolation Kit (Miltenyi
Biotech). NK cell purity was at least 95% of isolated cells.
Next, total RNA was isolated from a minimum of
100,000 cells with the NucleoSpin RNA II kit (Macherey-
Nagel). The RNA sample was then used for cDNA synthesis,
which was performed with random hexamers (MBI-Fer-
mentas) and RevertAid H Minus Reverse Transcriptase
(MBI-Fermentas). The final cDNA sample was used in
a RT-PCR reaction containing iQ SYBR Green Supermix
(Bio-Rad) and 1 mM of both forward and reverse primers.
All RT-PCR reactions were performed in duplicate with
the MyiQ2 Two-Color Real-Time PCR Detection System
(Bio-Rad). Primer sequences are shown in Table S3. These
experiments showed that ZBTB24 is ubiquitously ex-
pressed, and the highest expression levels are in B cell
subpopulations, most notably in naive B cells (Figure 3).
This corroborates the role of ZBTB24 in B cell differentia-
tion and is consistent with the observed B cell defects in
ICF patients.24rican Journal of Human Genetics 88, 796–804, June 10, 2011 799
Figure 2. ZBTB24 Mutations at the DNA and Protein Level
(A) Sanger sequencing results of seven ICF2 patients with ZBTB24mutations and an unrelated control individual. P1 carries a homozy-
gous 1 bp deletion resulting in a frameshift and a premature stop codon three amino acids downstream (p.Asn306IlefsX4). Both parents
are heterozygous carriers for the mutation, and the healthy brother is heterozygous as well (data not shown). P2 is homozygous for a
nonsense mutation resulting in a serine-to-stop conversion (p.Ser16X). P3 carries a homozygous sequence variant creating a premature
stop codon (p.Arg320X). Both parents are heterozygous carriers for the mutation (data not shown). P5 carries a homozygous 1 bp
800 The American Journal of Human Genetics 88, 796–804, June 10, 2011
Figure 3. ZBTB24 Expression
Full-length ZBTB24 expression levels
were measured in human primary cell
cultures (ES cells and fibroblasts; n ¼ 2),
in human tissues (alveoli, kidney,
liver, and thymus; n ¼ 1), in human cell
lines (HeLa, HCT116, JVM-2, Jurkat,
LCL, MOLT-4, Raji, Ramos, Tera-2,
and THP-1; n ¼ 1), in human B cells
(naive B cells [CD19þCD27IgDþ)],
unswitched memory B cells [CD19þ
CD27þIgDþIgMþ], switched memory B cells
[CD19þCD27þIgDIgM], and total B cells
[CD19þ]; n ¼ 2), in human CD4þ T cells
(naive CD4þ Tcells [CD4þCD45RAþCCR7þ],
memory CD4þ T cells [CD4þCD45RA],
and total CD4þ T cells [CD4þ]; n ¼ 2),
and in human NK cells (CD3CD56þ;
n ¼ 2). Expression levels were measured
in duplicate and are presented relative to
the expression levels of the three house-
keeping genes GAPDH, GUSB, and ACTB,
which were also measured in duplicate.
Data are presented as mean 5 standard
deviation.ZBTB24 (also known as ZNF450, BIF1, or PATZ2) contains
a BTB domain, a DNA-binding A-T hook domain, and eight
C2H2 zinc finger domains (Figure 2B). BTB domains are
found near the N terminus of several zinc finger proteins.
These domains mediate homomeric or heteromeric
dimerization between proteins25 and transcriptional
repression26 and have been shown to interact with histone
deacteylase corepressor complexes such as NCoR (nuclear
receptor corepressor), SMRT (silencing mediator of retinoic
acid and thyroid hormone receptor),27 and BCoR (BCL6
corepressor).28 A-T hook domains are DNA-binding motifs
present in many proteins, including the chromosomal
high-mobility group A (HMGA) proteins that are involved
in gene transcription, retroviral integration, neoplastic
transformation, and cancer cell metastasis.29
ZBTB24 is a member of a family of more than 40 human
ZBTB proteins, several of which play prominent roles in
hematologic differentiation.30 A well-studied ZBTB protein
is BCL6 (ZBTB27 [MIM 109565]), which was initially
identified as deregulated in certain B cell lymphomas by
chromosomal translocations.31 BCL6 seems to be required
for germinal center (GC) formation,32 represses gene func-
tioning during the terminal differentiation of B cells intoinsertion resulting in a frameshift and a premature stop codon 27 ami
heterozygous for a serine-to-stop nonsense mutation (p.Ser278X) an
homozygous for a nonsense mutation resulting in an arginine-to-st
for the mutation (data not shown).
(B) A schematic of the two isoforms of the ZBTB24 protein. The full-
acids 10–133), a DNA-binding A-T hook domain (amino acids 159–1
(amino acids 294–512). The shorter isoform 2 lacks seven C2H2 zin
sequence (an alternative stop codon is used in the intron between exo
used for RT-PCR. At least eight SNPs have been found in the coding s
indicated as well.
The Ameplasma cells,33 and binds to the p53 promoter, thereby
downregulating p53 expression in GC B lymphocytes
and lymphomas.34 Other ZBTB proteins, including
BCL6B (ZBTB28 [MIM 608992]),35,36 PATZ1 (ZBTB19
[MIM 605165]),37 ZBTB7B (MIM 607646),38,39 and
ZBTB32 (MIM 605859),40,41 have been implicated in
hematologic development and malignancies.42
Explaining the molecular mechanisms underlying ICF1
syndrome has been a challenge. DNMT3B is a ubiquitously
expressed enzyme central to mammalian biology. Dnmt3b-
knockout mice are embryonic lethal, and ICF1 syndrome
alleles should be considered hypomorphs.5 Two mecha-
nisms have been proposed to link DNMT3B defects to
compromised B cell immune responses. First, DNAmethyl-
ation of promoter regions of genes involved in B cell
differentiation might be disturbed. Indeed, a number of
transcriptionally deregulated genes have been identified
in EBV-transformed B cell lines of ICF patients, but only
a small proportion of them have significantly altered
DNA methylation promoter levels.43,44 Nevertheless, it is
conceivable that altered chromatin structures of some
master genes of B cell development contribute to ICF
pathology. A secondmechanism postulates that the alteredno acids downstream (p.Val168SerfsX28). P6 and P7 are compound
d a cysteine-to-glycine missense mutation (p.Cys408Gly). P10 is
op conversion (p.Arg457X). The mother is a heterozygous carrier
length ZBTB24 protein (isoform 1) contains a BTB domain (amino
71), and eight C2H2 zinc finger domains of 23 amino acids each
c finger domains, and the last 15 amino acids are an alternative
n 2 and exon 3). RNA ZBTB24 denotes the location of the primers
equence of ZBTB24. The numbers and locations of these SNPs are
rican Journal of Human Genetics 88, 796–804, June 10, 2011 801
chromatin structure of juxtacentromeric heterochromatin
and changes in the nuclear architecture lead to defects in
gene expression through effects in trans. Indeed, several
reports support this hypothesis by demonstrating altered
nuclear architecture and changes in chromosome territo-
ries with consequences for gene expression.45,46
Intriguingly, mice carrying ICF-like missense mutations
in Dnmt3b recapitulate some, but not all, molecular and
clinical features of ICF syndrome. These mice have hypo-
methylated repetitive DNA, low body weight, and cranial
facial abnormalities. However, these mice do not present
with a B cell defect; they have a normal spectrum of B
cell precursors and mature B cell populations. Instead,
these mice have reduced amounts of thymocytes and
increased levels of fragmented nuclei in the thymus.47
Although T cell defects have been rarely reported in ICF
syndrome, the presence of opportunistic infections in
ICF patients strongly argues for a (subtle) T cell defect in
ICF syndrome.2 In ICF patients, the early stages of B cell
development are reported to be normal, and the defect
mainly seems to arise in the peripheral terminal steps of
B cell differentiation. ICF patients have immature naive B
cells and impaired negative B cell selection. Although
patients have strongly reduced or absent immunoglobulin
levels, ICF B cells produce normal amounts of immuno-
globulins upon in vitro stimulation.24 These findings
strongly argue that the defect in ICF syndrome is restricted
to the latest stages of B cell development, possibly in
combination with an impaired T and B cell interaction.
The expression of ZBTB24 seems to be coregulated with
DNMT3B during B cell differentiation (Figure S1). There-
fore, to investigate direct effects of DNTM3B mutations
on ZBTB24 expression or vice versa, we studied the major
known splice variants of DNTMT3B (DNMT3B1,
DNMT3B2, DNMT3B3, DNMT3B4, and DNMT3B5) and
the presence of ZBTB24 in ICF1, ICF2, and control RNA
samples by nonquantitative RT-PCR. RNA and cDNA
samples were prepared in the same way as before, but the
final cDNA sample was used in a standard PCR reaction
containing DreamTaq DNA polymerase (Fermentas) and
1 mM of both forward and reverse primers (Table S3). All
DNMT3B splice variants and the ZBTB24 transcript could
be detected in ICF1, ICF2, and control samples
(Figure S2). Because our RNA sources came from different
origins, both primary cells and immortalized cell lines,
we refrained from quantitative analysis of DNMT3B and
ZBTB24 expression.
With the identificationofmutations inZBTB24, encoding
a member of a family of transcription factors important for
B andTcell differentiation,we expect thatmolecular studies
ofZBTB24will soonshedmore lightonthepathophysiology
of ICF syndrome and lymphocyte biology in general.Supplemental Data
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